Effect of Valproic Acid on Proliferation and Apoptosis of Hepatocellular Carcinoma HepG 2 Cell Line
Eucaryotic cells genomes are organized in chromatin whose basic repeating unit is the nucleosome which consists of 147 base pairs of DNA wrapped 1.7 times around an octamer of histone proteins (two each of histones H2A, H2B, H3, and H4). Histone modification such as histone acetylation affects chromatin structure and gene expression. In fact, acetylation of lysines is regulated by the opposing action of two families of enzymes containing histone acetyltransferases (HATs) and histone deacetylases (HDACs) that together determine the acetylation status of histones. The balance of histone acetylation and deacetylation plays a critical role in the regulation of gene expression. Aberrant activity of HDACs, however, leads to tumorigenesis. Histone deacetylase inhibitors (HDACIs) are a novel class of chemotherapeutic agents that target the classical HDAC enzymes by which activate differentiation programs, inhibit the cell cycle, and induce apoptosis. HDAC inhibitor valproic acid (VPA) has antitumor activities against certain cancers. The aim of the present study was to analyze the effect of VPA on proliferation and apoptosis of hepatocellular carcinoma HepG 2 cell line. Materials and Methods: MTT assay and flow cytometry assay were used to evaluate proliferative and apoptotic effects of VPA. Results: VPA inhibited the growth of HepG 2 cell and induced apoptosis significantly with a time- and dose-dependent manner. Discussion: Our finding clearly indicated that VPA has a significant inhibitory and apoptotic effects. Conclusion: VPA can significantly inhibit the growth and induce apoptosis in the HepG 2 cell line.
Kornberg RD, Lorch Y. Twenty-five years of the nucleosome, fundamental particle of the eukaryote chromosome. Cell. 1999; 98: 285–294.
Allfrey VG, Faulkner R, Mirsky AE. Acetylation and methylation of histones and their possible role in the regulation of RNA synthesis. Proc Natl Acad Sci USA 1964; 51:786-794.
Xhemalce B, Dawson MA, Bannister AJ. Histone modifications. In: Meyers R, ed. Encyclopedia of Molecular Cell Biology and Molecular Medicine. John Wiley and Sons, 2011: In Press.
Johnstone, R.W. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat. Rev. Drug Discov. 2002; 1: 287–299.
Iizuka, M., Smith, M.M. Functional consequences of histone modifications. Curr. Opin. Genet. Dev. 2003; 13: 154–160.
Luo JY, Su F, Chen DL, Shiloh A, Gu W. Deacetylation of p53 modulates its effect on cell growth and apoptosis. Nature. 2000; 408(6810):377–381.
de Ruijter AJ, van Gennip AH, Caron HN, et al. Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem J. 2003; 370 (3):737–749.
Gregoretti IV, Lee YM, Goodson HV. Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis. J Mol Biol. 2004; 338(1):17–31.
Marks, P., Rifkind, R. A., Richon, V. M., et al. Histone deacetylases and cancer: causes and therapies. Nat. Rev. Cancer. 2001; 1: 194–202, 2001.
Johnstone, R. W. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat. Rev. Drug Discovery. 2002; 1: 287–299.
Marks P, Rifkind RA, Richon VM. Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer. 2001; 1:194-202.
Johnstone RW. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat Rev Drug Discov. 2002; 1:287-99.
Kramer OH, Gottlicher M, Heinzel T. Histone deacetylase as a therapeutic target. Trends Endocrinol Metab 2001; 12:294-300.
Pandolfi PP. Histone deacetylases and transcriptional therapy with their inhibitors. Cancer Chemother Pharmacol 2001; 1: 17-9.
Yoshida M, Furumai R, Nishiyama M, et al. Histone deacetylase as a new target for cancer chemotherapy. Cancer Chemother Pharmacol 2001; 1: 20-6.
Sambucetti LC, Fischer DD, Zabludoff S, et al. Histone deacetylase inhibition selectively alters the activity and expression of cell cycle proteins leading to specific chromatin acetylation and antiproliferative effects. J Biol Chem 1999; 274:34940-7.
Archer SY, Hodin RA. Histone acetylation and cancer. Curr Opin Genet Dev 1999; 9:171-4.
Brown R, Strathdee G. Epigenomics and epigenetic therapy of cancer. Trends Mol Med 2002; 8: 43-8.
Laird PW. Cancer epigenetics. Hum Mol Genet 2005; 1: 65-76.
Miller TA, Witter DJ, Belvedere S. Histone deacetylase inhibitors. J Med Chem. 2003; 46: 5097-5116.
Marks PA, Richon VM, Miller T, Kelly WK. Histone deacetylase inhibitors. Adv Cancer Res. 2004; 91:137-168.
Yoshida M, Kijima M, Akita M, Beppu T. Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J Biol Chem. 1990; 265:17174-17179.
Yoshida, M., Kijima, M., Akita, M., et al. Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J. Biol. Chem., 1990; 265: 17174–17179.
Wharton, W., Savell, J., Cress, W. D., et al. Inhibition of mitogenesis in Balb/c-3T3 cells by trichostatin A–multiple alterations in the induction and activation of cyclin-cyclin-dependent kinase complexes. J. Biol. Chem. 2000; 275: 33981–33987
Yoshida, M., Hoshikawa, Y., Koseki, K., et al. Structural specificity for biological activity of trichostatin A, a specific inhibitor of mammalian cell cycle with potent differentiation-inducing activity in Friend leukemia cells. J. Antibiot. 1990; 43: 1101–1106
Vigushin, D. M., Ali, S., Pace, P. E., et al. Trichostatin A is a histone deacetylase inhibitor with potent antitumor activity against breast cancer in vivo. Clin. Cancer Res. 2001; 7: 971–976
Yoshida, M., Horinouchi, S., and Beppu, T. Trichostatin A and trapoxin: novel chemical probes for the role of histone acetylation in chromatin structure and function. Bioessays. 1995; 17: 423–430
Kwon, H. J., Owa, T., Hassig, C. A., et al. Depudecin induces morphological reversion of transformed fibroblast via the inhibition of histone deacetylase. Proc. Natl. Acad. Sci. USA. 1998; 95: 3356–3361
Marks, P. A., Richon, V. M., and Rifkind, R. A. Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J. Natl. Cancer Inst. 2000; 92: 1210–1216
Zhou, Q., Melkoumian, Z. K., Lucktong, A., et al. Rapid induction of histone hyperacetylation and cellular differentiation in human breast tumor cell lines following deg- radation of histone deacetylase-1. J. Biol. Chem.2000; 27: 35256–35263
Kosugi, H., Towatari, M., Hatano, S., et al. Histone deacetylase inhibitors are the potent inducer/enhancer of differentiation in acute myeloid leukemia: a new approach to antileukemia therapy. Leukemia (Baltimore). 1999; 13: 1316–1324
Masumeh Sanaei, Fraidoon Kavoosi and Shekoufeh Atashpour. Effect of Valproic Acid on Proliferation and Apoptosis of Colon Cancer HT 29 Cell Line. Global Journal of Medicine Researches and Studies. 2016; 3(1): 21-26
Tony Kouzarides. Chromatin Modifications and Their Function. 2007; Cell 128, 693–705
Bryan M. Turner. Histone acetylation and control of gene expression. Journal of Cell Science. 1991; 99, 13-20
Kalipso Halkidou, Luke Gaughan and Susan Cook et al. Upregulation and nuclear recruitment of HDAC1 in hormone refractory prostate cancer. Prostate. 2004; 59, 177–189.
Jaehwi Song, Ji Heon Noh, Jong Heun Lee et al. Increased expression of histone deacetylase 2 is found in human gastric cancer. APMIS. 2005; 113, 264–268.
Garea-Villar A and Steller M: Histone deacetylase inhibitors: understanding a new wave of anticancer agents. Int J Cancer. 2004; 112: 171-178.
Roth SY, Denu JM and Allis CD: Histone acetyltransferases. Ann Rev Biochem. 2001; 70: 81-120.
Garber K: Purchase of Aton spotlights HDAC inhibitors. Nat Biotechnol. 2004; 22: 364-365.
David Yu Greenblatt, Max A. Cayo, Joel T. Adler, et al. Valproic Acid Activates Notch1 Signaling and Induces Apoptosis in Medullary Thyroid Cancer Cells. Ann Surg. 2008; 247(6): 1036–1040.
Christopher S. Platta, B.S., David Yü Greenblatt, M.D., Muthusamy Kunnimalaiyaan. Valproic Acid Induces Notch1 Signaling in Small Cell Lung Cancer Cells. Journal of Surgical Research. 2008; 148 (1): 31–37.
Xiao-Nan Li, Qin Shu, Jack Men-Feng Su et al. Valproic acid induces growth arrest, apoptosis, and senescence in medulloblastomas by increasing histone hyperacetylation and regulating expression of p21Cip1, CDK4, and CMYC. Mol Cancer Ther 2005; 4(12):1912–22.
Richon VM, Sandhoff TW, Rifkind RA, Marks PA. Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc Natl Acad Sci U S A. 2000; 97:10014–10019.
Noriyuki Takai, Norihiko Kawamata, Dorina Gui et al. Human Ovarian Carcinoma Cells: Histone Deacetylase Inhibitors Exhibit Antiproliferative Activity and Potently Induce Apoptosis. Cancer 2004; 101: 2760–70.
Yasumichi Yagi1, Sachio Fushida1, Shinichi Harada et al. Effects of valproic acid on the cell cycle and apoptosis through acetylation of histone and tubulin in a cirrhous gastric cancer cell line. Journal of Experimental & Clinical Cancer Research 2010, 29:149.
Joseph J, Wajapeyee N, Somasundaram K: Role of p53 status in chemosensitivity determination of cancer cells against histone deacetylase inhibitor sodium butyrate. Int J Cancer 2005, 115:11-8.
Kitazono M, Bates S, Fok P, et al. The histone deacetylase inhibitor FR901228 (desipeptide) restores expression and function of pseudo-null p53. Cancer Biol Ther 2002, 1:665-8.
- There are currently no refbacks.
This work is licensed under a Creative Commons Attribution 3.0 License.
Copyright ©2013 Academic Journals Center
To make sure that you can receive messages from us, please add the 'academicjournalscenter.org' domain to your e-mail 'safe list'. If you do not receive e-mail in your 'inbox', check your 'bulk mail' or 'junk mail' folders.